Overview

  • Product nameAnti-MMP13 antibody [LIPCO IID1]
    See all MMP13 primary antibodies
  • Description
    Mouse monoclonal [LIPCO IID1] to MMP13
  • SpecificityThis antibody recognizes pro and active forms of MMP13. We have data to indicate that this antibody may not cross react with Human. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
  • Tested applicationsSuitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Mouse, Rat
    Does not react with: Human
  • Immunogen

    Rat MMP13 from BC-1 cells.

  • Positive control
    • Conditioned, serum free medium from (TPA treated) rat keratinocyte CCL-4 cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab80734 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 54 kDa. Incubate for 2 hours at room temperature.
IP Use at 2 µg/mg of lysate.

Target

  • FunctionDegrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
  • Tissue specificitySeems to be specific to breast carcinomas.
  • Involvement in diseaseDefects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
    Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
  • Sequence similaritiesBelongs to the peptidase M10A family.
    Contains 4 hemopexin-like domains.
  • DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • Database links
  • Alternative names
    • CLG 3 antibody
    • CLG3 antibody
    • Collagenase 3 antibody
    • Collagenase3 antibody
    • MANDP1 antibody
    • Matrix metallopeptidase 13 (collagenase 3) antibody
    • Matrix Metalloproteinase 13 antibody
    • Matrix metalloproteinase-13 antibody
    • MMP 13 antibody
    • MMP-13 antibody
    • Mmp13 antibody
    • MMP13_HUMAN antibody
    see all

Anti-MMP13 antibody [LIPCO IID1] images

  • Native IP using rat cells:
    Anti-MMP13 (biotin conjugated form of ab80734, containing BSA and azide) used for IP at 2 µg/mg lysate, and for subsequent WB at 1 µg/ml.
  • anti MMP13 (form of ab80734 containing BSA and azide) at 1 µg/ml + rat cells

    Predicted band size : 54 kDa
    Observed band size : 48,60 kDa (why is the actual band size different from the predicted?)

References for Anti-MMP13 antibody [LIPCO IID1] (ab80734)

ab80734 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab80734.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"